

**PDA**  
Pharmaceutical Research and Development Association  
India Chapter

## :Session 6: The Pivotal Case Study (How the “simple mistake” can lead to a warning letter)

Mr. S G Belapure, Zydus Cadila Healthcare  
Limited

Aseptic Processing Workshop:  
July 2014; Indore

---

---

---

---

---

---

---

---

---

---

**PDA**  
Pharmaceutical Research and Development Association  
India Chapter

### Aseptic Manufacturing.....Past to Present...

*Aseptic processing has improved remarkably since mid 1900's, including.....*

- Improved cleanroom garments and a better understand of modes of contamination
- Improved cleanroom designs and operational performance
- More comprehensive employee training and qualification programs.
- Improved aseptic processing equipment requiring fewer line interventions
- Well-established validation programs incorporating sound change-control practices to ensure continuing reliability of the processes
- Implementation of advanced contamination control technologies such as isolators, restricted access barrier systems (RABS).

Slide 2

---

---

---

---

---

---

---

---

---

---

**PDA**  
Pharmaceutical Research and Development Association  
India Chapter

### Drug Shortages .....

*Drug Shortages: Dosage Form wise*

| Dosage Form                | Percentage |
|----------------------------|------------|
| Injectable                 | 70%        |
| Tablet / Capsule           | 18%        |
| Oral Suspension / Solution | 3%         |
| Inhalation                 | 2%         |
| Transdermal / Dermal       | 2%         |
| Other                      | 1%         |
| Suppository                | 1%         |

*Injection Shortages: Reasons*

| Reason             | Percentage |
|--------------------|------------|
| Quality Issues     | 56%        |
| Capacity Issues    | 20%        |
| Discontinuation    | 9%         |
| Loss of Mfg Site   | 7%         |
| Other / Unknown    | 4%         |
| Raw Material (API) | 1%         |
| Component Problem  | 1%         |

Source: US Drug Shortages by Kaiser/Wesly, 2011  
Slide 3

---

---

---

---

---

---

---


---

---

---






  
 2  
**Is this Important to you?**  
  
**Yes!**

*Since January 2010, FDA has issued 66 compliance actions with failure to adequately train employees as one of the issues – at finished dosage sites alone!*

**This includes 28 Warning Letters, 3 injunctions and 1 seizure.**

Slide 10

---

---

---

---

---

---

---

---

---

---

**Quality.....Common Deficiencies**  
Training.....WL Examples

- o Your firm failed to ensure that each person engaged in the manufacture, processing, packing or holding of a drug product has the education, training and experience, or any combination thereof to enable that person to perform his or her assigned function.
- o For example: an employee examining microbial plates was unable to read and accurately record microbial counts.
- o Employee functioning in roles supporting your sterile operations that were not following the procedures that govern their activities, such as glove change frequency, handling of dropped objects, personnel monitoring and sample acquisition.
- o Other WL related training deficiencies:
  - o Training for specific job functions
  - o Training for general cGMP
  - o Repeated failure of personnel to follow procedures

Slide 11

---

---

---

---

---

---



---

---

---

---

**Quality.....Common Deficiencies / WL**  
Data Integrity.....

- Incomplete or altered data
- **Backdating**
- Fabricating data
- **Discarding data**
- **Testing into compliance**
- Failure to retain raw data
- Turning off audit trail capabilities
- **Password sharing / Common Password**
- Inadequate controls for access privileges
- Manipulating integration parameters

Slide 12

---

---

---

---

---

---

---

---

---

---

**Quality.....Common Deficiencies / WL**

**PDA**  
Pharmaceutical Packaging Association  
India Chapter

Quality Control Data

- Test results for one batch were used to release other batches (This occurred at least for 3 batches – at three unrelated firms)
- Destruction of raw data not meeting specification
- Missing raw data
- Re-writing laboratory note books
- Refusing to allow FDA to talk to employees
- Growth on microbiological plates was observed and recorded as no growth (Happened at three unrelated firms manufacturing sterile finished dosage forms)

Making up records during an FDA inspection

- Batch Records
- Training Records

Slide 13

---

---

---

---

---

---

---

---


---

---

**Quality.....Common Deficiencies / WL**

**PDA**  
Pharmaceutical Packaging Association  
India Chapter

Media Fills



- Reconciliations
- Not taking all the units filled.
- All operators / interventions are not included.
- + Ve / - Ve controls / GPT.
- Trained microbiologist / Operators for visual inspection of media fill vials.
- Not simulating actual process.

Slide 14

---

---

---

---

---

---

---

---



---

---

**Quality.....Common Deficiencies / WL**

**PDA**  
Pharmaceutical Packaging Association  
India Chapter

Personnel Practices



- Use of non-sterile gloves in aseptic area.
- Visible holes and flaking in the gloves. Broken primary packing of gloves.
- Rapid movement of the operators in the aseptic area.
- Not properly gowned. Loose head gear & goggle.
- Hand movements over the half stoppered vials.
- Use of non autoclavable papers and pens in the aseptic area.
- Keeping hands on waist when at rest.
- Frequent manipulations. Keeping entire body in the path of unidirectional airflow.

Slide 15

---

---

---

---

---

---








---

---

---

---

### Facility & Equipment.....Common Deficiencies / WL



■ Surfaces & Finishes...., Ducting & Piping...., Sinks & drains...  
■ **Toilet flush not working properly.**  
■ Cold Rooms: Water leakages and presence of microbial growth.  
■ Tools maintained in the aseptic area are rusted & not sterilized prior to use.  
■ **Use of adhesive taps.**  
■ **Rusting on light fixture. Dented doors. Chipping Paints.**  
■ Change Rooms....Gradient, Entry & Exit, Interlocking, Access Control  
■ Entry / Exit door into the vial filling area has no mechanism to slow the door when closing creating significant air flow disruption within the filling area.

Slide 16

---

---

---

---




---

---

---

---

### Production System.....Common Deficiencies / WL



■ Differences in automatic logging & then equipment manual entries for process controls.  
■ Reporting of deviation / incidence.  
■ **Sequential log not maintained.**  
■ Calibration / revalidation frequencies not maintained for equipment / instrument.  
■ **Not recording of all the steps involved in the process – carry out unauthorized steps.**

Slide 17

---

---

---

---



---

---

---

---

### Material System.....Common Deficiencies / WL



■ **Old & rejected lots were found.**  
■ Failed to determine why FIFO & CAPA was not followed.  
■ Manipulation in the RM reconciliation.  
■ No proper storage condition. Warehouse was not air conditioned.  
■ Vendor qualification - Supplier capability to control supply chain.  
■ **Wooden pallet – Not properly sanitized / treated – Fungus growth.**

Slide 18

---

---

---

---



---

---

---

---

### Packing & Labeling.....Common Deficiencies / WL



- Lack of written procedures describing identification, handling and examination.
- Validation of Pkg line is deficient.
- **Missing / error labels.**
- **Improper Line clearance.**
- No proper tracking system to back trace in case of any market complaint / recalls.
- No specimen or copy of approved label and all other labeling in the master production and control record.

Slide 19

---

---

---

---


---

---


---

---

### Laboratory Control.....Common Deficiencies / WL



- **All calculations are not included, performed during testing.**
- Failure to have a stability program to monitor stability characteristics.
- Reporting results without testing.
- **Use of trial injection.**
- **Unexplainable sequence of injection in HPLC – audit trails**
- **Unlabeled materials / Samples / Containers.**
- Established laboratory control mechanisms are not followed and documented at the time of performance.
- Failure to conduct thorough complaint investigations.
- No scientifically sound and appropriate specifications designed to assure identity, strength, quality and purity.
- No written records and appropriate validation data of computer or other automated processes.
- Disinfection Efficiency on different surfaces



Slide 20

---

---

---

---



---

---

---

---

### References.....



- PDA: Technical Report No. 22 (Revised 2011) Process Simulation for Aseptically Produced Products.
- Aseptic Processing: A Review of Current Industry Practice by James Agalloco, James Akers, and Russell Madsen, Pharmaceutical Technology, October, 2004.
- Guidance for Industry Sterile Drug Products Produced by Aseptic Processing —
- US Drug Shortages by Russel Wesdyk, 2011.
- "The Gold Sheet", March 2012.
- "The Gold Sheet", Feb 2014.
- Quality System, Part 1: Introduction to effective quality systems – organized by CDSCO & FDA, May, 2014.
- Validation times, June 2014.

Slide 21

---

---

---

---

---

---

---

---